This period, initiated by the industry ventures of Dr. Pharmacist Hakverdi Demir, laid the first foundations of many years of experience and expertise in healthcare.
The knowledge and experience gained formed the basis of the corporate structure and strong healthcare vision that would take shape in the years ahead, while also marking the first steps toward a culture of continuous development in the industry.
With a vision to provide medical solutions that meet international standards, the marketing rights for Bauerfeind products were acquired, laying the foundations for international partnerships.
This step helped Dem broaden its experience across different markets and strengthen its connections within the global healthcare industry.
.jpeg)
As years of industry experience evolved into a corporate vision, Dem Pharmaceuticals was founded and the foundations of the company’s long-term growth journey were laid.
With the strengthening of its corporate structure, its activities in healthcare expanded into a more comprehensive organization.
The launch of Somatosan, the first pharmacy product to reach healthcare professionals and patients directly, marked the beginning of a new era in Dem’s product portfolio.
This development strengthened the company’s presence in the pharmacy channel and expanded its market experience.
In line with the vision of improving access to biological and critical intensive care therapies, the addition of Grifols Human Albumin and Fanhdi to the portfolio significantly strengthened the company’s presence in critical treatment areas.
As a result, the product range and areas of expertise addressing diverse healthcare needs were expanded.
.png)
In line with the vision of improving access to biological and critical intensive care therapies, the addition of Grifols Human Albumin and Fanhdi to the portfolio significantly strengthened the company’s presence in critical treatment areas.
As a result, the product range and areas of expertise addressing diverse healthcare needs were expanded.
With the addition of Hibor and Thromboreductin to the portfolio, the product range in hematology and cardiovascular therapies was expanded.
This development strengthened Dem’s presence in specialized treatment areas and enabled its portfolio to become more comprehensive.
With the approval of Türkiye’s first biosimilar medicine, biotechnology initiatives gained momentum and an important step was taken toward establishing a vision for domestic biotechnological manufacturing.
This development provided a strong starting point for Dem’s long-term goals in innovative pharmaceutical technologies.
While the oncology portfolio was expanded with Oxalidem, Iritec and Gratyl, the company completed its first export following the licensing of Gemcibin and Zoloporoz.
These developments further strengthened product diversity and expertise in oncology and accelerated Dem’s expansion into international markets. The first successful export became an important milestone in the company’s growth journey across different regions.
The launch of Koate and Gamunex strengthened the product portfolio, while the approval of Türkiye’s first monoclonal antibody (mAb) biosimilar marked an important milestone in biotechnology.
This achievement further advanced the company’s capabilities in the field of advanced biotechnology.
The foundation of the Yalova Manufacturing Facility was laid with the goal of high-technology sterile and biotechnological manufacturing. This investment became an important part of Dem’s vision to increase domestic manufacturing capacity, integrate advanced technologies into production processes and manufacture in accordance with high quality standards.
The groundbreaking of the Yalova facility created a strong foundation for strengthening the company’s manufacturing infrastructure and supporting its long-term growth goals.
Following the successful completion of the Turkish GMP inspection, the first domestic production was carried out at the Yalova facility.
This marked the completion of an important stage in Dem’s manufacturing infrastructure and opened a new era in strengthening domestic production capacity for biotechnological and sterile products.
With the achievement of European Union (EU) GMP certification, the Yalova manufacturing infrastructure was officially recognized as compliant with international quality standards.
This important achievement helped advance Dem’s manufacturing capabilities on a global scale and supported its activities in international markets.
.png)
International reach was strengthened through new country approvals in Asian and Middle Eastern markets, while the commissioning of the solar power plant marked an important step in the company’s sustainable manufacturing vision.
These developments advanced Dem’s global growth objectives and environmental responsibility together.
